Tirzepatide has been shown in clinical trials to reduce the risk of cardiovascular events at various doses, suggesting a potential treatment option for patients who are obese or overweight [2]
Stay Informed Monitor emerging clinical trial data for CagriSema and other combinations Follow regulatory developments as new therapies approach approval Engage with continuing education on peptide mechanisms and applications 2
This dual mechanism is not just semaglutide with an extra ingredient
For example, one study found that 83% of 30 products tested had inaccurate labels and 7 of the 30 products contained hidden components not listed on the label
The results of the large cardiovascular event-driven safety trial comparing tirzepatide with dulaglutide in 12,500 participants in the SURPASS-CVOT study are expected in 2024 (78)
Clinical oversight is essential to confirm eligibility, evaluate sourcing and formulation quality, and ensure patient protection